Cannabis Law and Access in Brazil

Cannabis law in Brazil is not what the headlines suggest

Roughly 215 million people live under a cannabis regulatory system that sits somewhere between "strictly prohibited" and "cautiously open," and most English-language commentary gets the nuance badly wrong. Cannabis law in Brazil is not a story of legalisation. The country hasn't decriminalised possession in the way Portugal famously did. But it has built a layered, agency-driven access structure that is, in some respects, more permissive on importation of certain cannabinoid products than many people assume.

Working through comparative access frameworks across South America, Brazil keeps coming up. The gap between how journalists describe it and what the regulatory text actually says is wider than you'd expect, and that is a common pattern whenever foreign regulation is summarised in a headline. Reading the primary instruments, rather than a commentary on them, is the only reliable way to close that gap.

For Australian readers: nothing in this article is Australian law, and none of it changes your obligations or access pathways here. If you're looking for how AU scheduling works, our pages on the Special Access Scheme and Schedule 8 (Controlled Drug) classification are a better starting point. What follows is a factual account of Brazil's framework as it stands.

The baseline: cannabis is still a controlled substance in Brazil

Under Brazilian federal law, cannabis is classified as a prohibited substance under Portaria SVS/MS nº 344/1998, the national list of controlled substances maintained by ANVISA (Agência Nacional de Vigilância Sanitária), Brazil's equivalent of a combined TGA/FSANZ. Recreational use, cultivation, and commercial sale of cannabis plant material remain illegal. Possession of any quantity can attract criminal or administrative consequences, and the distinction between "user" and "trafficker" has historically been left to judicial discretion, which creates genuine legal uncertainty for individuals.

That baseline matters. A lot of coverage skips it.

The term controlled substance simply means a drug whose manufacture, supply and possession are governed by a formal list, with each entry carrying its own conditions. A listing is not the same thing as an absolute ban. Brazil's list is the legal anchor that every later resolution has had to work around, which is why ANVISA's instruments read as carve-outs from a general prohibition rather than as a new regime built from scratch.

The 2015 shift: ANVISA and the first importation window

The pivot point came in January 2015, when ANVISA issued a resolution permitting the importation of cannabidiol-based products for individual patients, on a case-by-case basis, following a high-profile legal battle by families of children whose doctors had recommended CBD-containing preparations. The resolution applied initially to products containing cannabidiol (CBD) with low or absent tetrahydrocannabinol (THC) content.

This wasn't legalisation. It was a supervised importation pathway, requiring documented medical need, a named prescribing physician, and product specifications. Think of it as structurally similar, though not legally identical, to Australia's own individual patient importation mechanisms. The gatekeeping was different, the product requirements were different, but the underlying logic of "controlled access via a regulatory agency" was comparable.

A common mistake is to read a pathway like this as a general right to obtain a product. Individual importation schemes are exceptions that depend on paperwork, a named clinician and an agency decision on each case. Anyone comparing countries should check who holds the decision, what documents are required, and what product details must be declared, because those three questions define how open a scheme really is.

RDC 327/2019: the first real regulatory architecture

ANVISA formalised its approach considerably with Resolution RDC 327, published in December 2019. This was the first instrument to create a proper registration and authorisation framework for cannabis-derived products in Brazil. Key features included:

• A pathway for domestic registration of cannabis-derived pharmaceutical products, subject to Good Manufacturing Practice requirements and product dossiers
• A prescription-only access model, products could only be dispensed with a medical prescription, with specific documentation requirements
• A continued individual importation authorisation pathway for patients whose needs weren't met by registered products
• Explicit limits on THC concentration in registered products (generally requiring THC to be minimal or within defined thresholds)

RDC 327/2019 also set out quality requirements including specifications for Good Manufacturing Practice compliance, the same international standard that underpins pharmaceutical-grade production globally. Products containing primarily CBD, with or without minor cannabinoids, were the primary target of the new framework.

A product dossier, in plain terms, is the file a manufacturer submits so a regulator can assess identity, quality and manufacturing controls. Registration is therefore about the product and the site that makes it, not about any claim regarding what the product does. Keeping that distinction in mind helps when reading any country's cannabis rules.

What changed with RDC 660/2022

In March 2022, ANVISA updated the framework again with RDC 660, which expanded the scope of registrable cannabis products and clarified requirements for domestic manufacturing. Brazil was, by this point, actively developing a domestic licensed cultivation and processing industry, something that had no legal basis before 2019.

RDC 660 introduced stricter product categorisation, distinguishing between products with predominant CBD content and those with higher THC concentrations. Products with elevated THC remain subject to substantially more restrictive controls, reflecting the continued scheduling of THC as a psychoactive substance requiring tighter oversight.

Honestly, the 2022 resolution is where Brazil's framework starts to get genuinely interesting from a regulatory design perspective. ANVISA made a deliberate choice to allow broader access to CBD-dominant preparations through a streamlined prescription pathway, while keeping high-THC products in a more controlled lane. Whether that distinction holds up scientifically, given what we know about how full-spectrum preparations work and the role of cannabinoid ratios, is a separate question. But as a regulatory architecture, it's coherent.

Regulators draw lines like this because a line is administrable: a concentration threshold can be written into a specification and checked by a laboratory. Pharmacology rarely divides so neatly. That tension, between what is easy to regulate and what is fully understood, shows up in nearly every national framework.

Recreational cannabis: still firmly prohibited

None of the above changes the recreational picture. Brazil has not decriminalised personal possession at the federal level in any formal sense. There's a 2006 federal law (Lei nº 11.343) that theoretically removed custodial sentences for users in favour of administrative measures, but in practice the judicial interpretation of "personal use" versus "trafficking" has remained inconsistent and often harsh. Several Brazilian states and municipalities have taken more permissive local stances, but these do not override federal criminal law.

Cultivation for personal use is not legally protected. Industrial hemp cultivation, defined by THC content thresholds, has been the subject of regulatory proposals, but as of the time of writing, no general-purpose hemp agriculture licensing scheme is operational at scale.

For a sense of how the medicinal and non-medicinal tracks diverge in law, see our explainer on the medicinal versus recreational legal distinction. Brazil is a clear example of a country where the two tracks run on entirely separate legal footings.

What products are available through legal channels

Registered or authorised cannabis-derived products in Brazil are, in practice, CBD-dominant pharmaceutical preparations dispensed under medical prescription. The pharmacokinetic profiles of these products, absorption rate, bioavailability, and first-pass metabolism considerations, are subject to the same scientific variables that apply to cannabinoid preparations globally. Oral and sublingual preparations are the most common forms.

Some preparations contain minor cannabinoids alongside CBD. Whether a given formulation qualifies as broad-spectrum, full-spectrum, or isolate-based is a product-level characterisation rather than a regulatory classification in Brazil's current framework; ANVISA focuses on active constituent concentrations rather than on extract category labels.

That matters for anyone reading product literature from any country. Terms such as "full-spectrum" are descriptive labels used by manufacturers, and they are not always defined in law. The enforceable information is usually the declared concentration of each active constituent, which is why regulators anchor on it.

What Brazil's framework does and doesn't assume about the science

ANVISA's decisions have tracked, broadly, the international evidence base. The agency has cited data from peer-reviewed literature in its resolution preambles, and RDC 327 explicitly referenced the importance of scientific evidence in determining access conditions. But Brazilian regulators have been careful, in my reading of their published instruments, not to overstate what the evidence shows. The framework permits access under medical oversight; it does not endorse specific outcomes.

The endocannabinoid system and the role of CB1 and CB2 receptors in human physiology are areas of active research internationally. Brazil's regulatory approach reflects a position of cautious scientific engagement rather than either prohibition-first conservatism or uncritical liberalisation. I'd argue that's actually a reasonable place to land, even if the implementation has been slow and the domestic industry still nascent.

Evidence quality is worth keeping in view here. Permission to prescribe a product is a regulatory decision about quality, supply and oversight. It is not a finding that research has established any particular result, and readers should be wary of any summary that blurs the two.

What this means for Australian readers

If you're in Australia and reading this out of curiosity about how other countries structure cannabis access, the comparison is worth making carefully. Australia's own framework, involving the Therapeutic Goods Administration, the ARTG, and pathways including the Authorised Prescriber scheme, operates under a different legislative basis entirely. The Poisons Standard (the current iteration of which is the Therapeutic Goods (Poisons Standard; October 2024)) governs scheduling here; Brazilian law has no bearing on Australian access, prescribing, or importation. The Therapeutic Goods Administration publishes the official position, and our piece on understanding the Special Access Scheme in Australia sets out one of the pathways in general terms.

If you're an Australian considering any medicinal cannabis access, the pathway runs through a registered medical practitioner and the TGA. Full stop.

But as a case study in how a large, middle-income country has tried to thread the needle between prohibition and access? Brazil's post-2015 journey is worth understanding. The architecture isn't perfect. The gap between the regulatory text and lived experience for Brazilian patients is still significant. And the absence of any recreational reform means millions of people remain exposed to criminal risk for activity that is tolerated, quietly, in many urban contexts.

Comparisons with other countries are useful too; our pages on cannabis law in South Africa and cannabis law in Mexico show very different routes to different outcomes.

Regulation catches up slowly. That's true in Brasília and it's true on Northbourne Avenue in Canberra too, if we're being fair about it.

Sources

• ANVISA RDC 660/2022, ANVISA (Brazilian Health Regulatory Agency)
• Cannabis regulation in Latin America: a comparative review, NCBI / PubMed
• Cannabidiol (CBD) Critical Review Report; World Health Organization
• Medicinal Cannabis Guidance Documents, Therapeutic Goods Administration (Australia)

Marcus Hale, Regulatory researcher, TGA & access law